Quantcast

Latest fatty liver Stories

2014-08-27 08:24:05

MarketOptimizer.org adds new clinical trial report "Fatty Liver Disease Global Clinical Trials Review, H2, 2014" to its store. DALLAS, Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver Disease Global Clinical Trials Review, H2, 2014 provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recruitment status as per the site...

2014-08-06 08:31:42

PORTLAND, Oregon, August 6, 2014 /PRNewswire/ -- A new report by Allied Market Research entitled, "Nonalcoholic Steatohepatitis Market (Pipeline analysis, drug class and Geography) Global Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 - 2020", indicates that the global nonalcoholic steatohepatitis (NASH) market would reach $1.6 billion by 2020 registering CAGR of 25.6% from 2014 to 2020. The high prevalence of Type II diabetes and obesity, which lead...

2014-07-25 04:21:20

PARIS, July 25, 2014 /PRNewswire/ -- New publication in Nature by international research team including Enterome scientific founder Professor Dusko Ehrlich ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, and with a strong focus on liver diseases, highlights the advanced online publication in Nature (ref. 1) of a research paper describing...

2014-07-22 08:32:59

TEL AVIV, Israel, July 22, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that the U.S. Food and Drug Administration, or the FDA, cleared Galmed's Investigational New Drug, or IND, application. Such clearance will permit Galmed to conduct clinical trials of...

2014-07-21 10:59:26

Massachusetts General Hospital Daily treatment with tesamorelin for six months lowered liver fat modestly but significantly The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. In a paper that will appear in the July 23/28 issue of JAMA – a theme issue on HIV/AIDS receiving early online release to coincide with...

2014-07-15 23:10:56

The Fatty Liver Bible & Ezra Protocol review that was just updated by Vkool.com reveals Debra Elkin’s home treatment system that promises efficiency in treating fatty liver and obesity. Seattle, Wa (PRWEB) July 15, 2014 According to the Fatty Liver Bible & Ezra Protocol review recently updated by Vkool.com, this is a helpful guide that provides readers with a wide range of tips and advice on how to resolve fatty liver and obesity. This book consists of 8 chapters including:...

2014-07-08 12:28:47

TEL AVIV, Israel, July 8, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed") today announced the recent publication of the results of its Phase IIa clinical trial of aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal. The trial manuscript, entitled "The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients with Nonalcoholic Fatty Liver Disease," provides the full report of the Phase IIa trial, which was...

2014-07-01 16:29:45

NY Times Article Brings Attention to Dangerous Lifestyle Related Epidemic and Suggests Critical Need for Therapy DENVER, July 1, 2014 /PRNewswire/ -- A recent New York Times article ("Threat Grows from Liver Illness Tied to Obesity", June 13 2014) alerting millions to the growing prevalence and seriousness of fatty liver disease revealed a stark and very concerning reality about therapeutic options. There are currently no drugs approved for either NAFLD (nonalcoholic fatty liver...

2014-06-23 09:37:29

Monash University An international team of scientists led by Monash University researchers has shown how free radicals contribute to type 2 diabetes, obesity and fatty liver disease. Type 2 diabetes and non-alcoholic fatty liver disease are key complications of obesity as 80 per cent of patients with type 2 diabetes are obese, and 75 per cent of patients who are obese or have type 2 diabetes also have fatty liver disease. The team, led by Professor Tony Tiganis from the Department...

2014-06-23 08:28:45

Company Presents Positive Preclinical Efficacy Results at ICE/ENDO 2014 Meeting RALEIGH, N.C., June 23, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin),...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related